Financials in USD. Standardized financial statements.
A compact view of how Calliditas Therapeutics AB (publ) turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.21B | $802.88M | $229.35M | $874,000 | $184.83M | $0 | $0 | $497,000 | $478,000 |
| Revenue Growth? | +50.3% | +250.1% | +26141.1% | -99.5% | 0.0% | 0.0% | -100.0% | +4.0% | 0.0% |
| Cost of Revenue? | $77.06M | $15.20M | $0 | $0 | $0 | $51,000 | $51,000 | $56.52M | $51.39M |
| Gross Profit? | $1.13B | $787.68M | $229.35M | $874,000 | $184.83M | -$51,000 | -$51,000 | -$56.02M | -$50.91M |
| Gross Margin? | +93.6% | +98.1% | +100.0% | +100.0% | +100.0% | 0.0% | 0.0% | -11271.6% | -10650.8% |
| Operating Expenses? | $1.51B | $1.21B | $753.80M | $383.10M | $212.71M | $133.20M | $84.65M | $56.52M | $51.39M |
| Operating Income? | -$384.40M | -$421.94M | -$524.46M | -$379.72M | -$28.02M | -$132.48M | -$84.51M | -$56.02M | -$50.91M |
| EBITDA? | -$367.80M | -$388.82M | -$471.83M | -$379.40M | -$30.35M | -$133.14M | -$84.60M | -$56.40M | -$51.28M |
| Income Before Tax | -$457.02M | -$409.42M | -$513.37M | -$436.15M | -$32.50M | -$132.05M | -$86.79M | -$56.91M | -$51.01M |
| Income Tax Expense | $9.17M | $2.85M | -$3.84M | $360,000 | $77,000 | $441,000 | $0 | $0 | $9,000 |
| Net Income? | -$466.19M | -$412.27M | -$509.54M | -$436.51M | -$32.58M | -$132.05M | -$86.79M | -$56.91M | -$51.01M |
| EPS? | $-17.38 | $-15.56 | $-20.04 | $-19.46 | $-1.76 | $-5.08 | $-5.12 | $-3.42 | $-3.08 |
| Diluted EPS? | $-17.38 | $-15.56 | $-20.04 | $-19.46 | $-1.76 | $-5.08 | $-5.12 | $-3.42 | $-3.08 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality